Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as paclitaxel, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving sorafenib together with
paclitaxel may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving sorafenib together with
paclitaxel and to how well it works in treating patients with metastatic breast cancer.